HIND (Vyome Holdings Inc.) stock: $2.10, $14.7M market cap, $7.9M cash, $7.6M EV, $18.5M fully diluted market cap. Data from Fully Diluted's biotech stocks database.
Share price
$2.10
Market cap
$14.7M
Cash
$7.9M
Enterprise value
$7.6M
Balance sheet
Cash
$7.9M
Debt
$0.8M
Net cash
$7.1M
Enterprise value
$7.6M
Basic shares
7.0M shares
Fully diluted shares
8.8M shares
Fully diluted market cap
$18.5M
Cash per share
$1.13
Cash figures as of 2026-06-30. Database snapshot: 2026-09-21.
Price history
Loading HIND daily closes…
Loading price history…
Pipeline assets
VT-1953
Phase 2 · ActiveModality: topical gel
Aliases VB-1953
Target DNA Gyrase/Topoisomerase
Indications
malodor of malignant fungating wounds (MFW) in advanced cancer(Phase 2)
Catalysts
— first half of 2026
Status note Lead program (post-August 2025 merger with Vyome). Dual DNA Gyrase/Topoisomerase inhibitor and immunomodulator topical gel; same active agent as an FDA-approved eye drop (NDA#22-308) for bacterial conjunctivitis. Phase 1 (2017) and Phase 2 randomized dose-ranging studies completed; VB-1953 QD dose supported for Phase 3; pivotal study design to be informed by Phase 2. Investigator-initiated study ongoing in malodorous MFW. VT-1908 also listed in the biotechnology segment but undescribed in excerpts.
Luliconazole
Approved · ActiveModality: topical
Partnerships Sun Pharma: development and licensing agreement for additional development and commercialization in India (sales commenced)
Indications
anti-fungal (topical)(Approved)
Status note Anti-fungal product commercialized in India via Sun Pharma; also a reformulated topical anti-fungal shampoo based on the MRT platform commercialized in India. No specific indication named in excerpts.
Per-asset detail extracted from the 10-Q filed 2026-08-12. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.
No lead program on file for this company.
No active ClinicalTrials.gov trials matched to this company as sponsor or collaborator.
No specialist-fund holders in 13F data for this company.
Get the weekly biotech catalyst rundown. Cash runways, financings, and trial readouts for all 714 stocks.